Arkolith/Insider Trading/ZBIO/Form 4

Nunn Jason Raleigh

DirectorZenas BioPharma, Inc. (ZBIO) · full profile →Form 4 · filed Sep 16, 2024
Net Buying
Open-Market Buys
$15.0M
Open-Market Sells
$0
Net Open-Market Flow
$15.0M
Transactions
7
4 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 16, 2024Buy(P)441K$17.00$7.5M1.1M
Sep 16, 2024Conversion(C)669K——669K
Sep 16, 2024Buy(P)441K$17.00$7.5M1.9M
Sep 16, 2024Conversion(C)1.5M——1.5M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Sep 16, 2024Conversion(C)5.8M——0
Sep 16, 2024Conversion(C)13.1M——0
Sep 12, 2024Grant(A)37K—$037K

Transaction Codes

P
Open-market purchase
C
Conversion of a derivative
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-24-106979) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML